GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (NAS:SNDX) » Definitions » Shareholder Yield %

Syndax Pharmaceuticals (Syndax Pharmaceuticals) Shareholder Yield % : 0.52% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Syndax Pharmaceuticals Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Syndax Pharmaceuticals's Shareholder Yield % was 0.52%.


Syndax Pharmaceuticals Shareholder Yield % Historical Data

The historical data trend for Syndax Pharmaceuticals's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Shareholder Yield % Chart

Syndax Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -52.65 -0.04 0.57 0.52

Syndax Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 1.03 1.36 1.44 0.52

Competitive Comparison of Syndax Pharmaceuticals's Shareholder Yield %

For the Biotechnology subindustry, Syndax Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Shareholder Yield % falls into.



Syndax Pharmaceuticals Shareholder Yield % Calculation

Syndax Pharmaceuticals's Shareholder Yield % for the quarter that ended in Dec. 2023 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0 %+0 %+0.52 %
=0.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Syndax Pharmaceuticals  (NAS:SNDX) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Syndax Pharmaceuticals Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Syndax Pharmaceuticals (Syndax Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, Building D, Floor 3, Waltham, MA, USA, 02451
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Executives
Briggs Morrison director, officer: Chief Executive Officer C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
William Meury director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Neil Gallagher officer: President, Head of R&D 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Peter Ordentlich officer: Chief Technology Officer C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Michael A Metzger officer: President and COO C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Steve M Sabus officer: Chief Commercial Officer 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Catherine Madigan officer: Chief Medical Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Alexander Nolte officer: Chief Accounting Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Fabrice Egros director C/O SYNDAX PHARMACEUTICALS, INC., TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Huber Martin H. Jr. director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Daphne Karydas officer: Chief Financial Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451

Syndax Pharmaceuticals (Syndax Pharmaceuticals) Headlines

From GuruFocus